GEP20197007B - Therapeutic agent for frontal lobe dysfunction - Google Patents
Therapeutic agent for frontal lobe dysfunctionInfo
- Publication number
- GEP20197007B GEP20197007B GEAP201614604A GEAP2016014604A GEP20197007B GE P20197007 B GEP20197007 B GE P20197007B GE AP201614604 A GEAP201614604 A GE AP201614604A GE AP2016014604 A GEAP2016014604 A GE AP2016014604A GE P20197007 B GEP20197007 B GE P20197007B
- Authority
- GE
- Georgia
- Prior art keywords
- therapeutic agent
- frontal lobe
- lobe dysfunction
- dysfunction
- frontal
- Prior art date
Links
- 230000004064 dysfunction Effects 0.000 title abstract 2
- 210000001652 frontal lobe Anatomy 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015055532 | 2015-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20197007B true GEP20197007B (en) | 2019-07-25 |
Family
ID=56919157
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201614604A GEP20197007B (en) | 2015-03-19 | 2016-03-18 | Therapeutic agent for frontal lobe dysfunction |
| GEAP201914604A GEAP201914604A (en) | 2015-03-19 | 2016-03-18 | Therapeutic agent for frontal lobe dysfunction |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201914604A GEAP201914604A (en) | 2015-03-19 | 2016-03-18 | Therapeutic agent for frontal lobe dysfunction |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US20180042910A1 (pl) |
| EP (1) | EP3270923B1 (pl) |
| JP (1) | JP6869893B2 (pl) |
| KR (1) | KR20170129764A (pl) |
| CN (1) | CN107405341A (pl) |
| AR (1) | AR103972A1 (pl) |
| AU (1) | AU2016234211B2 (pl) |
| BR (1) | BR112017018165A2 (pl) |
| CA (1) | CA2978426A1 (pl) |
| CL (1) | CL2017002351A1 (pl) |
| CO (1) | CO2017008814A2 (pl) |
| CR (1) | CR20170405A (pl) |
| CY (1) | CY1124459T1 (pl) |
| DK (1) | DK3270923T3 (pl) |
| DO (1) | DOP2017000206A (pl) |
| EA (1) | EA032511B1 (pl) |
| EC (1) | ECSP17069712A (pl) |
| ES (1) | ES2884846T3 (pl) |
| GE (2) | GEP20197007B (pl) |
| HR (1) | HRP20211340T1 (pl) |
| HU (1) | HUE055387T2 (pl) |
| IL (1) | IL254196A0 (pl) |
| JO (1) | JO3544B1 (pl) |
| LT (1) | LT3270923T (pl) |
| MX (1) | MX381277B (pl) |
| MY (1) | MY196076A (pl) |
| PE (1) | PE20171621A1 (pl) |
| PL (1) | PL3270923T3 (pl) |
| PT (1) | PT3270923T (pl) |
| RS (1) | RS62311B1 (pl) |
| SG (1) | SG11201707012YA (pl) |
| SI (1) | SI3270923T1 (pl) |
| SV (1) | SV2017005527A (pl) |
| TN (1) | TN2017000369A1 (pl) |
| TW (1) | TWI723012B (pl) |
| UA (1) | UA123578C2 (pl) |
| WO (1) | WO2016148308A1 (pl) |
| ZA (1) | ZA201706136B (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113016719B (zh) * | 2019-12-24 | 2022-08-02 | 复旦大学附属华山医院 | 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69834500T2 (de) | 1997-09-05 | 2007-05-03 | Kyowa Hakko Kogyo Co., Ltd. | Xanthinderivative zur behandlung von hirnischämie |
| JP4638355B2 (ja) | 2003-12-26 | 2011-02-23 | 協和発酵キリン株式会社 | チアゾール誘導体 |
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| TWI548411B (zh) * | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
| UA113383C2 (xx) * | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів | |
| UA110097C2 (uk) * | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
-
2016
- 2016-03-17 JO JOP/2016/0045A patent/JO3544B1/ar active
- 2016-03-18 UA UAA201709985A patent/UA123578C2/uk unknown
- 2016-03-18 MX MX2017012020A patent/MX381277B/es unknown
- 2016-03-18 RS RS20211061A patent/RS62311B1/sr unknown
- 2016-03-18 PL PL16765135T patent/PL3270923T3/pl unknown
- 2016-03-18 HR HRP20211340TT patent/HRP20211340T1/hr unknown
- 2016-03-18 AU AU2016234211A patent/AU2016234211B2/en not_active Ceased
- 2016-03-18 EA EA201792070A patent/EA032511B1/ru unknown
- 2016-03-18 HU HUE16765135A patent/HUE055387T2/hu unknown
- 2016-03-18 MY MYPI2017703320A patent/MY196076A/en unknown
- 2016-03-18 AR ARP160100730A patent/AR103972A1/es unknown
- 2016-03-18 KR KR1020177026576A patent/KR20170129764A/ko not_active Withdrawn
- 2016-03-18 GE GEAP201614604A patent/GEP20197007B/en unknown
- 2016-03-18 WO PCT/JP2016/059788 patent/WO2016148308A1/en not_active Ceased
- 2016-03-18 EP EP16765135.5A patent/EP3270923B1/en active Active
- 2016-03-18 US US15/558,240 patent/US20180042910A1/en not_active Abandoned
- 2016-03-18 SI SI201631316T patent/SI3270923T1/sl unknown
- 2016-03-18 DK DK16765135.5T patent/DK3270923T3/da active
- 2016-03-18 PT PT167651355T patent/PT3270923T/pt unknown
- 2016-03-18 BR BR112017018165A patent/BR112017018165A2/pt not_active Application Discontinuation
- 2016-03-18 LT LTEP16765135.5T patent/LT3270923T/lt unknown
- 2016-03-18 CN CN201680012849.8A patent/CN107405341A/zh active Pending
- 2016-03-18 ES ES16765135T patent/ES2884846T3/es active Active
- 2016-03-18 CR CR20170405A patent/CR20170405A/es unknown
- 2016-03-18 PE PE2017001525A patent/PE20171621A1/es unknown
- 2016-03-18 SG SG11201707012YA patent/SG11201707012YA/en unknown
- 2016-03-18 GE GEAP201914604A patent/GEAP201914604A/en unknown
- 2016-03-18 JP JP2017547186A patent/JP6869893B2/ja not_active Expired - Fee Related
- 2016-03-18 TW TW105108544A patent/TWI723012B/zh not_active IP Right Cessation
- 2016-03-18 TN TNP/2017/000369A patent/TN2017000369A1/en unknown
- 2016-03-18 CA CA2978426A patent/CA2978426A1/en not_active Abandoned
-
2017
- 2017-08-29 SV SV2017005527A patent/SV2017005527A/es unknown
- 2017-08-29 IL IL254196A patent/IL254196A0/en unknown
- 2017-08-29 CO CONC2017/0008814A patent/CO2017008814A2/es unknown
- 2017-09-08 ZA ZA2017/06136A patent/ZA201706136B/en unknown
- 2017-09-11 DO DO2017000206A patent/DOP2017000206A/es unknown
- 2017-09-15 CL CL2017002351A patent/CL2017002351A1/es unknown
- 2017-10-18 EC ECIEPI201769712A patent/ECSP17069712A/es unknown
-
2021
- 2021-08-25 CY CY20211100762T patent/CY1124459T1/el unknown
- 2021-09-03 US US17/466,772 patent/US20210393606A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| ZA201603342B (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| GEAP202014670A (en) | Agents, Uses and Methods for the Treatment of Synucleinopathy | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| MY187540A (en) | Compounds active towards bromodomains | |
| SG10201809153WA (en) | Muscle atrophy inhibitor containing quercetin glycoside | |
| TN2019000210A1 (en) | Antitumoral compounds | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
| MX2019005833A (es) | Administracion transdermica de agentes grandes. | |
| MX375438B (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| PH12018501943A1 (en) | Pharmaceutical compositions for the treatment of cancer | |
| IN2013MU03118A (pl) | ||
| PH12017501897A1 (en) | 2-thiopyrimidinones | |
| MX2017007318A (es) | Metodos de prevencion, reduccion o tratamiento de degeneracion macular. |